

Our Position on *Access*

We believe...

in **better access to quality medicines and vaccines**, particularly for the underserved population and vulnerable communities **across all geographies**, to foster economic growth, social inclusion, and environmental protection

We offer...

approaches adapted to the specifics of both healthcare systems and patient needs through **commercial, social, and philanthropic models to provide global access** to our medicines, vaccines, and health solutions.

We ask...

for a **true partnership between biopharmaceutical industry, health authorities and payers** to equitably reward the value of medicines and vaccines while sharing the responsibility of maintaining sustainable investment in Research and Development.

- Medicines and vaccines bring value to healthcare systems and wider society, and we are determined to ensure that they are accessible to patients in need.
- Broadening access to medicines and vaccines requires adaptation to the specifics of healthcare systems in each country; adjustment to patient needs; recognition of the value they provide to whole society today; and continued investment in the development of therapies that will improve the lives of patients tomorrow.
- Access to healthcare, treatments and vaccines requires continuous collaboration, commitment and a common agenda between patients, health authorities, payers, and industry.

- Sanofi has multiple strategies to broaden access, including our patient assistance programs and net price flexibility to reflect both the holistic value of our innovation and the capacity of countries to pay for it.
- We provide broader access to essential medicines through a non-profit business unit for global health that will operate in 40 countries (among the lowest per capita GDP nations), improving access for the most disadvantaged people in the world to 30 essential medicines (*) that we produce at Sanofi.

Footnote: () According to the WHO list of Essential Medicines*

- Governments and payers to take decisions in the long term that look beyond the management of immediate budget constraints, consider the holistic value of medicines and vaccines, and include the cost of investing today for the security of tomorrow's supply.
- Wealthier countries to make a greater commitment that incentivizes continued investment in innovation through policies that recognize and reward the value of improving the lives of future patients around the world.
- Governments to work in partnership with industry, payers, and patients, setting up early and long-term collaboration to address future access challenges, including stable methods to assess the value of medicines and vaccines, as well as sufficient resources to finance them.

